An objective look at the EASD 2026 data preview, distinguishing promising early trial results for obesity treatments from established clinical guidance.
On September 28, 2026, Medical Daily published an extensive data preview for the 62nd annual meeting of the European Association for the Study of Diabetes. This major scientific conference is taking place in Milan from September 28 to October 2. The coverage highlighted numerous presentations focusing on emerging obesity and diabetes medicines. These presentations included data on investigational drugs alongside studies evaluating existing treatments.
The scientific gathering serves as a critical venue for pharmaceutical companies to share recent clinical trial outcomes. These early findings often generate significant media attention regarding the future of metabolic healthcare. Beyond the conference presentations, the broader pharmaceutical sector continues to show intense activity. A separate September 2026 report noted that Novo Nordisk agreed to license an experimental obesity pill.
This licensing agreement involves Jiangsu Hengrui Pharmaceuticals in a deal worth as much as $2.6 billion. Such financial investments highlight a strong commercial interest in developing new oral obesity treatments. However, commercial activity does not represent finalized clinical evidence for patients. Understanding the distinction between a financial milestone and a medical reality is a crucial part of navigating weight-management news.
The medications discussed at the conference operate through specific physiological pathways rather than generic calorie suppression. Retatrutide is a notable investigational drug featured prominently in the latest trial data. It functions as a once-weekly, three-receptor agonist acting on GIP, GLP-1 and glucagon receptors. Targeting three distinct hormone receptors simultaneously is designed to influence metabolic function in a coordinated manner.
Kenneth Custer, Ph.D., president of Lilly Cardiometabolic Health, emphasized the clinical reasoning behind this approach. He stated that meeting the needs of people living with diabetes or obesity requires multiple treatment options based on different mechanisms. This biological reality aligns with our foundational approach to metabolic health at WeightRestart. Weight change is never simply a matter of willpower, but rather a complex interplay of biology, environment and targeted medical treatments.
When the new class of weight-loss medications started dominating the news, the media reaction was entirely polarized. It was presented either as a complete medical cure or as a moral failing. I saw a huge need for calm, objective reporting. We decided to cover these medications exactly like any other tool by examining the clinical data without any judgment.
The response from our readers showed just how starved people were for facts over feelings. Our editorial process prioritizes clarity over sensationalism so our readers can make informed decisions. When individuals understand that medications act on specific hormone pathways, they realize their past struggles were biological rather than personal failures. This knowledge supports a body-neutral approach to health by focusing on measurable metabolic improvements instead of shame.
It is easy to see flashy headlines and assume that medical guidelines have shifted overnight. According to Medical Daily, most of the newly previewed figures were company topline results or conference abstracts. These initial formats differ significantly from finalized, peer-reviewed papers. While these early announcements are informative, the newly previewed findings did not change current prescribing guidance.
One highly discussed result involved the SURPASS-CVOT cardiovascular study. The report says tirzepatide, marketed as Mounjaro, was non-inferior to Trulicity for a combined outcome of heart attack, stroke or cardiovascular death. This trial focused specifically on adults with type 2 diabetes and established heart disease. While the data showed an 8% lower risk with Mounjaro, the finding had a confidence interval of 0.83 to 1.01.
Because this confidence interval crosses 1.0, the report cautions that the finding did not establish a clear cardiovascular advantage over Trulicity. When statistical data includes a confidence interval that crosses 1.0, researchers cannot definitively claim the treatments have different outcomes. A non-inferiority finding means a new option is a safe alternative, but it does not prove it is a universally superior choice.
A similar statistical reality appeared in Lilly’s Foundayo cardiovascular results. The preview described these as non-inferiority findings where the reported risk reductions had confidence intervals crossing 1.0. Consequently, the data did not establish superiority over the comparator.
The preview also examined the U.S. OCTANE study regarding medication transitions. This study evaluated three-month, real-world weight outcomes after patients switched from injectable semaglutide or tirzepatide to the Wegovy pill. The preview characterizes these data as observational and short-term, meaning they cannot definitively forecast long-term individual outcomes.
The conference materials provided specific clinical metrics for several investigational treatments. During the Phase 3 TRIUMPH-2 trial, researchers monitored adults with overweight or obesity and type 2 diabetes. Eli Lilly reported up to 20.8% average weight loss at 80 weeks with investigational retatrutide. This significant percentage translates to an average reduction of up to 49.6 pounds.
Additionally, the trial noted A1C reductions of up to 1.6 percentage points over the same period. While these numbers are compelling, reviewing how they were calculated is essential for accurate comprehension. The report clarifies that these TRIUMPH-2 figures use an "efficacy estimand." This specific statistical model estimates results as if every participant had remained on treatment without interruption.
Therefore, these numbers should not be read as a straightforward estimate of what every person starting treatment will experience. The distinction between an efficacy estimand and a real-world outcome is fundamental to health literacy. In an ideal trial setting, patients have access to structured support and perfect medication adherence. Real life involves missed doses, side effects and changing personal circumstances.
When pharmaceutical developers use an efficacy estimand, they are showing the biological potential of a drug under optimal conditions. Understanding these analytical frameworks helps patients evaluate clinical trial data with a clear perspective. Learning how to properly interpret trial percentages protects readers from developing inaccurate treatment expectations. Currently, retatrutide remains strictly investigational and is not an approved therapy.
Scientific conferences offer a valuable preview of where metabolic medicine is heading next. However, substantial future research is needed before these early findings can formally reshape everyday clinical practice. The medical community must wait for full peer-reviewed publications to validate the initial conference abstracts. Regulatory agencies will eventually review the complete clinical data from trials like TRIUMPH-2 and SURPASS-CVOT.
Only after this rigorous independent evaluation will clinical guidelines officially update to incorporate these new mechanisms. Until then, these promising investigational figures represent biological possibilities rather than immediate medical realities. Medical Daily explicitly advises against changing or stopping a current medication based solely on conference headlines. Patients interested in how these developments might impact their care should discuss possible treatment changes with a qualified prescriber.
Having an informed conversation with a physician is crucial for sustaining results safely and effectively. As new data undergoes rigorous evaluation, relying on established clinical guidelines remains the most prudent approach.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
